Catalyst Pharmaceuticals, Inc. provided earnings guidance for the year 2022. For the year, the company expects total revenues to be in the range of between $195 million and $205 million, representing a 38%45% increase in total revenues as compared to 2021.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
15.12 USD | +0.30% | -0.40% | -10.05% |
05/06 | Catalyst Pharmaceuticals Insider Sold Shares Worth $276,735, According to a Recent SEC Filing | MT |
30/05 | Sector Update: Health Care Stocks Mixed Late Afternoon | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.05% | 1.78B | |
+2.97% | 94.74B | |
-3.68% | 37.28B | |
-12.22% | 32.68B | |
+74.21% | 27.72B | |
-14.28% | 16.19B | |
-2.41% | 13.88B | |
-12.21% | 11.58B | |
+188.83% | 10.92B | |
-53.94% | 9.54B |
- Stock Market
- Equities
- CPRX Stock
- News Catalyst Pharmaceuticals, Inc.
- Catalyst Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022